Consider CorMedix (CRMD), a highly profitable healthcare company trading at an exceptionally low P/E ratio of 5.66 despite its projected 120% forward revenue growth. The company's sales are expected to nearly double to $400 million in 2025, driven by its FDA-approved anti-infection product, DefenCath. For a higher-risk opportunity, look at KULR Technology Group (KULR), a deep-tech battery safety company whose stock is beginning to be valued for its core business beyond its Bitcoin holdings. The investment thesis is that the market is correcting a major mispricing, offering potential for continued upside as the company grows. When investing in such volatile small-cap stocks, it is crucial to use common stock rather than options and be prepared for significant price swings.

CorMedix (CRMD)

• Business Overview: CorMedix is a healthcare company whose main product is DefenCath, an FDA-approved anti-infection fluid used to prevent infections in dialysis catheters. This is a significant issue, as infections are a leading cause of death for dialysis patients.
  • The product saves Medicare money (by preventing expensive infection treatments) and makes money for dialysis centers (who get reimbursed more for having fewer infections).
  • The company has a concentrated customer base with the two largest dialysis organizations, Davita and Fresenius, as its main clients.
• Financials & Growth: The speaker highlights extremely strong financial metrics and growth prospects.
  • Valuation: Described as "dirt, dirt, dirt cheap," with a P/E ratio of 5.66, which is considered exceptionally low for a company with its growth profile. The speaker notes this is a P/E ratio more typical of a failing retail store.
  • Growth: Forward revenue growth is estimated at 120%. The company is guiding for a doubling in sales, from $214 million (trailing 12 months) to around $400 million in 2025.
  • Profitability: The company "prints cash" with a 96% gross margin and a 41% EBITDA margin.
  • Market Opportunity: The potential market for DefenCath alone could be $5 to $10 billion at maturity. There is also a large expansion opportunity in selling the product for use with TPN (feeding) catheters in hospitals.
• Strategic Acquisition: CorMedix recently acquired Melinta, another company in the anti-infection space.
  • This diversifies their product line with antifungal and antibacterial products.
  • It creates synergies, as the same sales team can sell both DefenCath and Melinta's products.

Takeaways

• Bullish Thesis: The core investment thesis is that CorMedix is a rapidly growing, highly profitable company trading at an extremely low valuation. The speaker believes the market is misclassifying it as a risky, pre-revenue biotech stock when it is actually a cash-generating commercial-stage company with a protected, FDA-approved product.
• Valuation Anomaly: An investor might see this as an opportunity where the company's strong fundamentals (high growth, high margins) do not align with its low stock valuation (P/E of 5.66).
• Long-Term Hold: Despite a recent 24% run-up, the speaker believes the stock is still significantly undervalued and holds it for the long term.

KULR Technology Group (KULR)

• Business Overview: KULR is described as a "deep tech" company specializing in battery management and thermal runaway systems (preventing batteries from catching fire). It is an early-stage, pre-cash flow company that is investing heavily in growth and production expansion.
  • Their technology is used in high-stakes applications, with customers including the Department of Defense and products used in space (batteries on the Moon and Mars).
• The Valuation Anomaly: The primary attraction for the speaker was a significant market mispricing.
  • A few weeks prior, the company's market capitalization was less than the value of the Bitcoin it held on its balance sheet.
  • This meant an investor was essentially getting the entire deep-tech business—with its patents, defense contracts, and space technology—for a negative value.
• Reason for Mispricing: The speaker believes KULR was incorrectly lumped into a "basket" of stocks related to the "digital asset treasury company trade." When sentiment turned negative on that theme, KULR was sold off indiscriminately, regardless of its underlying business fundamentals.
• Bitcoin as a Strategic Asset: The speaker views the company's Bitcoin holdings as a major positive.
  • It provides a "margin of safety" for the investment.
  • It gives the company a way to finance its growth by borrowing against the Bitcoin or selling small portions, potentially avoiding shareholder dilution from issuing new stock.

Takeaways

• Bullish Thesis: The market is beginning to correct its mistake and value KULR for its core technology business, not just its Bitcoin holdings. This is evidenced by the stock rising 74% in 19 days while the price of Bitcoin has fallen, showing a clear "disassociation."
• Anomaly Investing: This is an example of an investment based on a market anomaly. The opportunity was to buy the company's assets (Bitcoin) for less than they were worth and get the promising technology business for free.
• Higher Risk Profile: This is a classic "hyper-growth" small-cap investment. It is not yet profitable and is burning cash to grow. The investment carries higher risk than a company like CorMedix, but the valuation anomaly provided a unique, asymmetric risk/reward opportunity.

Small-Cap Investing Strategy

• The speaker outlines three key rules for investing in volatile, high-growth small-cap stocks like CRMD and KULR.

Takeaways

• Rule 1: Avoid Options. Small-cap stocks can remain undervalued for years. The time decay of options makes them extremely risky for this type of investing. If you must use them, the speaker suggests very long-dated options (900+ days), but advises sticking to common stock.
• Rule 2: Expect Insane Volatility. Investors must be mentally prepared for huge price swings. While this is increasingly true for large-cap stocks as well, it is a defining characteristic of the small-cap space.
• Rule 3: Look for Exceptional Valuation Anomalies. The market is not always rational. It often trades stocks in "baskets," leading to situations where good companies get sold off with bad ones. This can create opportunities to buy companies for less than their assets are worth (e.g., KULR trading for less than its Bitcoin holdings). An investor's job is to find these moments of irrationality.